Clinical data
ATC code
  • none
Legal status
Legal status
  • In general: uncontrolled
  • (5R)-5-{(1R)-2-[(4-methylphenyl)sulfonyl]-1,2,3,4-tetrahydroisoquinolin-1-yl}dihydrofuran-2(3H)-one
PubChem CID
Chemical and physical data
Molar mass371.45 g·mol−1
3D model (JSmol)
  • Cc1ccc(cc1)S(=O)(=O)N2CCc4ccccc4[C@@H]2[C@@H]3CCC(=O)O3

ROD-188 is a sedative drug that was structurally derived from the GABAA antagonist bicuculline by a team at Roche.[1] Unlike bicuculline, ROD-188 acts as an agonist at GABAA receptors, being a positive allosteric modulator acting at a novel binding site distinct from those of benzodiazepines, barbiturates or muscimol, with its strongest effect produced at the α6β2γ2 subtype of the GABAA receptor.[2] ROD-188 is one of a number of related compounds acting at this novel modulatory site, some of which also act at benzodiazepine receptors.[3][4]

See also


  1. ^ US 6649626, "N-substituted 1-(lactone) isoquinolones for treating nervous disorders" 
  2. ^ Thomet U, Baur R, Razet R, Dodd RH, Furtmüller R, Sieghart W, Sigel E (October 2000). "A novel positive allosteric modulator of the GABA(A) receptor: the action of (+)-ROD188". British Journal of Pharmacology. 131 (4): 843–850. doi:10.1038/sj.bjp.0703558. PMC 1572371. PMID 11030736.
  3. ^ Sigel E, Baur R, Furtmueller R, Razet R, Dodd RH, Sieghart W (June 2001). "Differential cross talk of ROD compounds with the benzodiazepine binding site". Molecular Pharmacology. 59 (6): 1470–1477. doi:10.1124/mol.59.6.1470. PMID 11353808.
  4. ^ Ramerstorfer J, Furtmüller R, Sarto-Jackson I, Varagic Z, Sieghart W, Ernst M (January 2011). "The GABAA receptor α+β-interface: a novel target for subtype selective drugs". The Journal of Neuroscience. 31 (3): 870–877. doi:10.1523/JNEUROSCI.5012-10.2011. PMC 3182524. PMID 21248110. S2CID 1989995.